Opendata, web and dolomites


IgA-based oral therapy for protection of piglets against infection with enterotoxigenic E. coli.

Total Cost €


EC-Contrib. €






 ImmunoFarm project word cloud

Explore the words cloud of the ImmunoFarm project. It provides you a very rough idea of what is the project "ImmunoFarm" about.

losses    platform    effect    rest    regular    soya    responsible    maternal    prophylaxis    performed    global    vitro    elite    thaliana    domains    transformants    etec    additive    negative    first    oligoclonal    vivo    format    postweaning    except    benthamiana    groups    formulation    f18    seed    piglets    caused    coli    transient    passive    assays    phage    pigs    display    strains    group    transferred    synergistic    twenty    pwd    antibodies    adhesion    obtain    pig    scalable    surfaces    world    strategy    predominantly    abundance    fimbriae    fight    formulations    receiving    illness    weaning    prophylactic    genes    economic    feed    enterotoxigenic    infections    industry    seeds    siga    expression    immunity    nicotiana    diarrhoea    anti    immunotherapy    prolong    cocktails    villus    f4    mucosal    antibiotics    resistance    host    vhhs    arabidopsis    lactogenic    rearing    bulk    treatment    agent    post    forbidden    biosafe    neutralisation    engineered    antibody   

Project "ImmunoFarm" data sheet

The following table provides information about the project.


Organization address
postcode: 9052

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2017-08-13


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB BE (ZWIJNAARDE - GENT) coordinator 160˙800.00


 Project objective

Postweaning diarrhoea (PWD) in pigs is responsible for important economic losses in the global pig rearing industry. This illness is predominantly caused by enterotoxigenic E. coli strains carrying the F4 (ETEC-F4) and F18 (ETEC-F18) fimbriae. There is no treatment available to fight PWD except using antibiotics. However, the prophylactic use of antibiotics is forbidden in Europe and is expected to become forbidden in the rest of the world because of increasing abundance of resistance genes. Delivery of sIgA to mucosal surfaces as passive immunotherapy agent is a very promising strategy to prolong maternal lactogenic immunity against post-weaning infections. The aim of this project is to produce sIgA-like anti-ETEC antibodies in a cost-effective platform. Twenty different anti ETEC-F18 antibodies in a sIgA-like format will be engineered from phage display-selected variable domains (VHHs) currently available in the host institute. The synergistic or additive neutralisation effect of oligoclonal antibody cocktails will be evaluated using ETEC-F18 in vitro villus adhesion assays. The different antibodies will be produced first by transient expression in Nicotiana benthamiana and second in seeds of Arabidopsis thaliana transformants. An in vivo ETEC-F18 challenge will then be performed using two groups of piglets, one receiving the most effective seed-derived feed formulations and the other one receiving regular feed (negative control group). The sIgA antibodies of the elite oligoclonal formulation will then be transferred to biosafe soya seeds as production platform. These steps will lead towards the development of scalable procedures to obtain a cost effective bulk production of a feed based prophylaxis against ETEC.


year authors and title journal last update
List of publications.
2016 Vikram Virdi, Paloma Juarez, Veronique Boudolf, Ann Depicker
Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles
published pages: 535-545, ISSN: 1420-682X, DOI: 10.1007/s00018-015-2074-0
Cellular and Molecular Life Sciences 73/3 2019-07-24
2016 Paloma Juarez, Vikram Virdi, Ann Depicker, Diego Orzaez
Biomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applications
published pages: n/a-n/a, ISSN: 1467-7644, DOI: 10.1111/pbi.12541
Plant Biotechnology Journal 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOFARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOFARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

GenEl (2020)

General readout electronics for cross-sectoral application in European research infrastructure

Read More  

SIMIS (2020)

Strongly Interacting Mass Imbalanced Superfluid with ultracold fermions

Read More  

iRhomADAM (2020)

Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling

Read More